Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-10

Clinical Trial Update: Neoadjuvant Pazopanib in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant pazopanib for renal cell carcinoma has completed, with results posted on May 10, 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Votrient (Pazopanib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-10